You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Johnson and Johnson
Harvard Business School
Mallinckrodt
Boehringer Ingelheim

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

APIDRA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for APIDRA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Medical University of WarsawPhase 4
Boston UniversityN/A
Massachusetts General HospitalN/A

See all APIDRA clinical trials

Recent Litigation for APIDRA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08

See all APIDRA litigation

Company Disclosures: US Patents for APIDRA

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi Aventis Us APIDRA insulin glulisine recombinant INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021629 001 2005-12-20   Start Trial Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE) 2017-06-20 DISCN company
Sanofi Aventis Us APIDRA insulin glulisine recombinant INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021629 002 2005-12-20   Start Trial Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE) 2017-06-20 DISCN company
Sanofi Aventis Us APIDRA SOLOSTAR insulin glulisine recombinant INJECTABLE;SUBCUTANEOUS 021629 003 2005-12-20   Start Trial Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE) 2017-06-20 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for APIDRA

These patents were identified by searching patent claims

Supplementary Protection Certificates for APIDRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SPC/GB05/024 United Kingdom   Start Trial PRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTERED: UK EU/1/04/285/001 20040929; UK EU/1/04/285/002 20040929; UK EU/1/04/285/003 20040929; UK EU/1/04/285/004 20040929; UK EU/1/04/285/005 20040929; UK EU/1/04/285/006 20040929; UK EU/1/04/285/007 20040929; UK EU/1/04/285/008 20040929; UK EU/1/04/285/009 20040929; UK EU/1/04/285/010 20040929; UK EU/1/04/285/011 20040929; UK EU/1/04/285/012 20040929; UK EU/1/04/285/013 20040929; UK EU/1/04/285/014 20040929; UK EU/1/04/285/015 20040929; UK EU/1/04/285/016 20040929; UK EU/1/04/285/017 20040929; UK EU/1/04/285/018 20040929; UK EU/1/04/285/019 20040929; UK EU/1/04/285/020 20040929
251 Finland   Start Trial
132005901285503 Italy   Start Trial PRODUCT NAME: INSULINA GLULISINE(APIDRA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/04/285/001-020, 20040927
2005C/006 Belgium   Start Trial PRODUCT NAME: INSULIN GLULISINE; AUTHORISATION NUMBER AND DATE: EU/1/04/285/001 20040928
122004000049 Germany   Start Trial PRODUCT NAME: INSULIN GLULISINE; REGISTRATION NO/DATE: EU/1/04/285/001-020 20040927
C00885961/01 Switzerland   Start Trial PRODUCT NAME: INSULIN GLULISIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57013 02.05.2005
CA 2005 00018 Denmark   Start Trial PRODUCT NAME: INSULIN GLULISIN
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Colorcon
Harvard Business School
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.